Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript

SA Transcripts 162.37K Followers Follow Sagimet Biosciences Inc. ( SGMT ) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne September 30, 2026 1:00 PM EDT Company Participants David Happel - CEO, President & Director Andreas Grauer - Chief Medical Officer Conference Call Participants Julie Harper Nathanael Charoensook - Leerink Partners LLC, Research Division Ritu Baral - TD Cowen, Research Division Boran Wang - Guggenheim Securities, LLC, Research Division Cheng Li - Oppenheimer & Co. Inc., Research Division Ioannis Souroutzidis - Cantor Fitzgerald & Co., Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Catherine Okoukoni - Citizens JMP Securities, LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Greetings, and welcome to the Sagimet Biosciences Key Opinion Leader Call. [Operator Instructions] As a reminder, this conference is being recorded and will be available for the replay on the Investors section of the Sagimet website following today's call. Before we begin, I would like to remind our listeners that our comments today will include some forward-looking statements. These statements include statements regarding the presentation of the data from our clinical trials, our clinical development plans and related and anticipated development milestones as well as Sagimet's cash and financial resources, financing and partnering plans, expected cash runway and related and anticipated development milestones. These statements involve a number of risks and uncertainties, which are outlined in the press release for this event and on Slide 2 of this presentation. Actual events or results may differ materially from those projected in the forward-looking statements, which contain known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. I would now like to turn the conference over to your host, Dave Happel. Thank you. You may now begin. David Happel